Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
433 Cards in this Set
- Front
- Back
typhoid is a _______________ infection
|
systemic;
starts at the GI, spread to other areas |
|
ALL enteroinvasive bact. are;
|
obligate intracellular pathogens
|
|
what kind of pathogen uses the zipper OR trigger mechanism of entry?
|
entero*invasive*
|
|
oocysts ~~
|
Cryptosporidosis
|
|
parentarel =
|
through other than the mouth
|
|
hepatitis: ALL 5 types infect:
|
hepatocytes
|
|
only patients already infected with Hep B can get:
|
Hep D
|
|
4 symptoms of hepatitis:
|
1. fatigue
2. nausea 3. fever 4. coke-urine |
|
specific diagnosis of hepatitis infection requires:
|
serologic testing
|
|
4 serum liver markers of hepatitis =
|
1. ALT
2. AST 3. bilirubin 4. alkaline phosphatase |
|
Hep A and E are shed from the liver in:
|
bile
|
|
A and E virions are:
(2) |
1. non-enveloped
2. stable in the environment |
|
Hep B, C, and D are NOT stable in:
|
the environment
|
|
"chronic" hepatitis ~~
|
longer than 6 months
|
|
Hepatitis A features:
(3) |
1. no envelope
2. (+) RNA 3. picornavirus family |
|
Hep A is REALLY stable against:
(2) |
1. high Temp
2. low pH |
|
***Hep A hijacks:***
|
**envelope from host** while inside the body
|
|
vaccine against Hep A is a:
|
whole virus vaccine
|
|
distinguishing features of Hep A infection:
(3) |
1. transferred by fecal-oral transmission
2. relapsing hepatitis is common 3. fulminant hepatitis is not uncommon |
|
**even after 2 weeks of infection with Hep A,**
|
giving a pt Hep A vaccine will prevent the disease
|
|
features of Hep C:
(2) |
1. (+) RNA
2. enveloped |
|
life cycle of Hep C: RNA into cytoplasm =>
|
replication assembly line => membranous web (vesicles) => replication
=> extracellular release OR spread to adjacent cell |
|
Hep C usurps:
|
MANY host factors in order to replicate
|
|
***in order to spread extracellularly, Hep C takes over:***
|
VLDL
=> circulates within apolipoproteins |
|
Hep C's diversity/variability of surface proteins =>
|
chronic infections
|
|
***___% of peope will be persistently infected with Hep C until treated***
|
70%
|
|
a person persistently infected with Hep C will be aymptomatic until:
|
he starts noticing symptoms of liver cirrhosis
|
|
Hep C is able to suppress:
|
the II signaling pathways that sense viral RNA
|
|
immunity against Hep C is:
|
questionable
|
|
Hep C infection is diagnosed by:
(2) |
1. Hep C AB's
2. RNA PCR |
|
treatment of Hep C =
|
Direct-Acting Antivirals
- MUST be used in *combos* to avoid R |
|
Hep B = DNA virus that:
|
replicates through an RNA intermediate
|
|
**Hep B uses ____ to replicate**
|
RT
DNA to RNA back to DNA via RT |
|
**Inhibition of RT will suppress Hep B, but will not:**
|
produce immunity, since the cccDNA is still found as a plasmid in the nucleus
|
|
___% of people with Hep B are *asymptomatic*
|
50%
|
|
**almost all adults infected with Hep B:**
|
clear the infection
|
|
**infants and immunocompromised have a high risk of:
|
NOT clearing a Hep B infection and thus becoming life-long carriers
|
|
co-infection of Hep B with Hep D greatly increases:
|
the risk of mortality
|
|
markers of Hep B infection, **acute OR chronic:**
(2) |
HBsAg + = infectious
HBeAg + = highly infectious |
|
IgM HBc AB + =
|
*acute* Hep B infection
|
|
HBs AB + =
|
full immunity
|
|
transmission of Hep B comes via:
(4) |
1. mother to fetus at birth
2. b/w young children 3. sexual (common and efficient) 4. shared needle (parentenal) |
|
treatment of Hep B:
|
RT >> interferon
- goal is *suppression* of the disease, to prevent cirrhosis, liver failure, and HCC |
|
first-line oral antiviral for Hep B =
|
tenofavir
|
|
second-line antiviral for Hep B =
|
adefovir
|
|
Hep B vaccine is:
|
great
- first cancer vaccine, because it challenges HCC |
|
Strongyloides is NOT:
|
a hookworm
|
|
When you see metronidazol, think:
(3) |
1. anaerobics
2. parasites 3. bact. causes of vaginosis |
|
most common STI in the US =
|
Chlamydia
|
|
except for syphilis, women tend to:
|
have STI's more
|
|
exposure to STI does NOT mean:
|
infection of STI
|
|
"natural history" of the infection =
|
how you got expose, then infected; what stage of the infection you're in, etc.
|
|
3 reasons why adolescent women tend to have greater rates of STI's:
|
1. fewer Lactobacilli => higher vaginal pH
2. thinner genital tract mucus 3. cervical ectopy |
|
cervical ectopy =
|
squamo-columnar epithelium of the cervix (aka endocervix) extends down into the vagina
=> easier for pathogens to attach - adults have just squamous epithelium there |
|
ectopy = part of body is in:
|
abnormal position
|
|
first-line defense against STI pathogens =
(2) |
1. genital epithelium
2. mucous |
|
second line of defense against STI pathogens =
|
II
- which includes TLR's and antimicrobial peptides |
|
third line of defense against STI pathogens =
|
AI
|
|
AI defense against STI pathogens includes:
(3) |
1. IgA in cervix and urethra
2. IgG in vaginal/semen secretions 3. T cells (most abundant in the lower genital tract) |
|
**risk factors for STI's**
(2) |
1. multiple partners
2. ...at the SAME TIME |
|
vaccines against STI's are:
|
RARE
- only 2 |
|
the only 2 vaccines against STI's =
|
1. HPV vaccine
2. Hep B vaccine |
|
3 major bacterial ST pathogens =
|
1. Chlamydia
2. N. gonorrhea 3. Treponema pallidum (syphilis) |
|
major protozoan that causes STI's =
|
Trichomonas vaginallis
(trichomoniasis) |
|
**many STI's cause NO:
|
(or mild) signs/symptoms
|
|
genital herpes are often:
|
recurrent
|
|
some ST pathogens gain access to the body via the mucosal surfaces, but:
|
DON'T affect the mucosa
- others DO cause mucosal disease |
|
***4 common features of ST pathogens:***
|
1. **NOT found free in the environment**
2. **humans are the ONLY reservoir** 3. commonly asymp, b/c microbes are NOT eliminated by the IS 4. no vaccines (except HPV and Hep B) |
|
women are often:
|
asymptomatic with STI's
|
|
2 adverse effects of STI on a woman's reproductive health:
|
1. ascending infection (damage due to host response)
2. bad pregnancy outcomes |
|
3 results of infections that STI's cause women:
|
1. PID
2. infertility 3. ectopic pregnancy |
|
bad pregnancy outcomes due to STI include:
(3) |
1. preterm birth
2. low birth weight 3. infections of infant during vaginal birth |
|
asymptomatic does NOT mean:
|
inconsequential
|
|
synergy of STI's and HIV: STI's increase:
|
the risk of acquisition/transmission of HIV
|
|
how do STI's increase the risk of acquisition/transmission of HIV?
(2) |
1. breaking mechanical barriers to HIV
2. increasing inflammation => brings HIV-susceptible cells to sight of HIV |
|
active STI ~~ more likely to:
|
have/get HIV
|
|
microscopy ~~
(2) |
1. low sensitivity
2. high specificity |
|
culture ~~ high:
|
specificity
|
|
**we CANNOT culture:**
|
T. pallidum bact.
|
|
virus cultures take more:
|
time/effort/money
|
|
**not all STI's produce:**
|
an AB response
|
|
serology detects:
|
AB's in the serum
- indicative of past infection |
|
serology is sometimes able to distinguish between:
|
acute and chronic infections
|
|
**syphilis infection produces 2 kinds of AB's:**
|
1. AB's the recognize cardiolipin on *host* membranes
2. AB's that T. pallidum antigens |
|
AB's that recognize host cardiolipin are detected by:
|
**non-treponemal tests**
|
|
2 names of non-treponemal tests:
|
RPR, VDRL
|
|
non-treponemal tests have high sensitivity but modest specificity; =>=>
|
**screening tests**
- need to be confirmed by trep tests |
|
(other conditions, including pregnancy and rheumatoid arthritis, also make:
|
AB's against host cardiolipin
=> have to confirm that it's syphilis) |
|
AB's against T. pallidum antigens are detected by:
|
**treponemal tests**
- TPPA, TPHA |
|
**treponemal AB's stick around; =>
|
treponemal tests remain positive even after treatment**
(non-trep AB's do NOT => non-trep tests are negative after treatment) |
|
2 test approaches for syphilis:
|
1. old-school
2. new approach |
|
old-school approach to test for syphilis:
(2) |
1. use non-trep first
2. if positive, confirm with treponemal test |
|
interpreting the old-school test results:
(3) |
1. if non-trep is negative, pt does NOT have syphilis
2. if positive / trep-negative, pt. does NOT have syphilis 3. if pos / pos, pt. HAS syphilis |
|
what is the new-school approach to treating syphilis?
(2) |
1. use new, fast Tp
2. if pos, use non-trep |
|
new-school approach: what does it mean if the Tp is positive, but the non-trep is negative?
(3 possible meanings) |
1. pt could have had treated or untreated syphilis in the past
2. pt has early, primary syphilis 3. Tp was a false positive. |
|
NAAT is a great:
|
non-invasive way of testing for STI's
|
|
syphilis: men have it more, and it's:
|
rising
|
|
syphilis has lethal synergy with HIV:
(4) |
1. syphilis destroys epithelial barrier via genital ulcers
2. recruits HIV-susceptible cells into its lesions 3. patients with early syphilis have high HIV loads 4. risk of neurosyphilis is 3-5x greater in pts with HIV |
|
stages of syphilis: incubation period (3 weeks) =>
|
primary syphilis => secondary => latent period => tertiary
|
|
neurosyphilis =
|
T. pallidum is IN the CNS
|
|
neurosyphilis can occur at ANY:
|
stage of syphilis
|
|
later forms of neurosyphilis affect:
|
the actual brain and SC
|
|
primary syphilis:
(3) |
1. ~ painless ulcer
2. ...in anogenital region and mucous membranes (including lips, tongue, cheeks, fingers) 3. ...that heals in a few weeks |
|
secondary syphilis ~~
|
spread of spirochetes
|
|
secondary syphilis strikes a few weeks after:
|
the disappearance of the ulcer
|
|
secondary syphilis ~ systemic symptoms:
(4) |
1. malaise
2. fever/head 3. sore throat 4. hepatitis |
|
***indicative symptoms of secondary syphilis = ***
(2) |
maculopapular rash and condyloma lata
|
|
maculopapular =
|
red and raised
|
|
condyloma lata =
|
genital warts
|
|
**secondary syphilis will resolve in:**
|
an immunocompetent person
|
|
latent syphilis:
(2) |
1. asymp
2. either early or late |
|
early latent syphilis ~~
(<1 year) |
**infectious**
|
|
late latent syphilis ~~
(2) |
1. non-infectious (except mother to child)
2. longer course of treatment |
|
diagnosis of latent syphilis is made ONLY:
|
with blood test
|
|
tertiary syphilis occurs:
|
10-30 years after initial infection
|
|
without therapy, latent syphilis becomes some form of tertiary syphilis in:
|
1/3 of patients
|
|
tertiary syphilis can result in:
(3) |
1. neurosyphilis
2. cv problems 3. gummatous cyphilis |
|
gummatous syphilis =
|
nasty ulcers on the skin
|
|
50% of pregnancies of women infected with syphilis =>
|
miscarriage
|
|
40-70% of infants born to women with syphilis have:
|
congenital syphilis
|
|
congenital syphilis ~~
|
characteristic bone/eye/ear/brain damage
- including Hutchinson's incisors (moon-shaped bites) |
|
syphilis is caused by:
|
Treponema pallidum
|
|
Treponema palladum:
(3) |
1. spirochete
2. **outer membrane lacks LPS** 3. **very few exposed proteins** |
|
Treponema pallidum CANNOT grow in:
|
culture
|
|
pathology of T. palladum:
(2) |
1. spirochetes attach *anywhere* - can infect many tissues
2. active motility is essential for invasion and dissemination |
|
no LPS of spirochetes =>
|
TLR4 is NOT activated
|
|
b/c very few spirochetes' proteins are not exposed on the surface, spirochetes can:
|
escape immediate detection
|
|
**spirochetes do NOT release:**
|
toxins
|
|
early syphilic lesions ~
(2) |
CD4+, CD8+ cells
=> activated macrophages infiltrate the lesion |
|
**AB's against T. palladum can opsonize and neutralize, but CANNOT:
|
prevent future infections of syphilis
|
|
treatment of syphilis:
(3) |
1. 1 dose of penicillin cures primary OR secondary infections
2. use Z-pak if can't tolerate penicillin 3. R to Z-pak is rising |
|
Trichomona vaginallis infects:
|
both males and females
|
|
Trichomona is found ONLY in:
|
the human genital tract
- no other reservoir |
|
Trichomoniasis is the most common:
|
non-viral STI
|
|
in women, prevalence of Trichomoniasis increases with:
|
age
|
|
Trichomona is a:
|
protozoan parasite
|
|
Trichomoniasis is associated with:
|
HIV and other STI's
|
|
Trichomona vaginalis lacks mit. and instead has:
|
hydrogenosomes
|
|
treatment of of Trichomoniasis reduces:
|
**HIV RNA in vaginal fluid**
|
|
**Trichomoniasis has STRONG synergy with:**
|
HIV
|
|
clinical presentation of Trichomoniasis in women:
(3) |
1. common site of infection = vagina, urethra, endocervix
2. frothy vaginal discharge, strawberry cervix 3. odor, itching, dysuria |
|
dysuria =
|
painful or difficult urination
|
|
clinical presentation of Trichomoniasis in men:
(4) |
1. watery discharge
2. urethritis 3. dysuria 4. though it's commonly asymp |
|
73% of women are symptomatic with:
|
Trichomoniasis
- 77% of men are ASYMP |
|
immune response to Trichomoniasis:
(2) |
1. NO protection from re-infection
2. inflammation is associated with influx of neutrophils |
|
diagnostics of Trichomoniasis:
(4) |
1. wet mount microscopy -
2. culture 3. rapid antigen 4. NAAT's |
|
wet mount microscopy requires:
(2) |
1. vaginal swab/male urine sediment
2. must be performed within 15 minutes |
|
wet mount for Trichomoniasis is NOT:
|
a great diagnostic
|
|
treatment of Trichomoniasis =
(2) |
metronidazole,
tinidazole |
|
metronidazole and tinidazole are activated within:
|
hydrogenosomes
=> toxic nitro-radicals that target parasite DNA and prot's |
|
R of Trichomona to metronidazole:
|
increasing
|
|
N. gonorrhea is also called:
|
gonococcus / GC
|
|
gonorrhea is also called:
(2) |
the clap,
the drip |
|
gonorrhea is MOSTLY _____________ but can have a:
|
asymptomatic;
broad spectrum of clinical presentations |
|
***there is no such thing as a ____________________ of gonorrhea***
|
chronic carrier
- if you have it, you're ALWAYS infected, b/c it's a frank pathogen |
|
uncomplicated gonorrheal infections take of the form of ____________________ in men
|
urethritis
|
|
UGI's take the form of ____________________ in women
(2) |
1. cervical inf's
2. urethral inf's |
|
cervicitis ~
|
pus of neutrophils
|
|
UGI's can also be:
(2) |
1. oropharyngeal infections (in both men and women)
2. rectal infections (esp. with MSM) |
|
pharyngitis ~
|
inflamed throat
|
|
**watch out when testing throat for UGI, because the throat sometimes contains:**
|
N. minigicoccus as normal flora
- **identical** to N. gonorrhea in gram stain |
|
symptoms of UGI (urethritis) in men:
(3) |
1. abrupt onset
2. dysuria 3. profuse, purulent discharge |
|
apart from male urethritis, all other UGI's are:
|
often asymptomatic and hard to differentiate from other STI's
|
|
gonoccocal conjuctivitis:
(2) |
1. rare in adults
2. acquired by newborns during passage through infected birth canal |
|
2 kinds of complicated gonorrheal infections (CGI's):
|
1. PID
2. GCI |
|
PID stands for:
|
pelvic inflammatory disease
|
|
PID =
(3) |
endometritis, salpingitis, pelvic peritonitis, and inflammation of other parts of the female repro system
|
|
PID features:
(2) |
1. occurs within a few days of menses
2. **occurs in 10-20% of women with cervititis** |
|
DGI stands for:
|
disseminated gonococcal infection
|
|
DGI occurs when:
|
GC enters bloodstream => skin and joints => rashes and arthritis
- rare |
|
N. gonorrhea are GN _____________
|
*diplococci*
|
|
N. gonorrhea are really good at:
|
taking up DNA => variation/R
|
|
N. gonorrhea are R to:
(2) |
1. neutrophils' ROS
2. regular bacteriocidal effects of human serum |
|
what are the 2 pathogenic Neisseria?
|
1. N. gonorrhea
2. N. meningococcus |
|
N. gonorrhea - no capsule =
|
rare that it would disseminate
|
|
N. gonorrhea do NOT have:
|
a capsule
- N. meningicocci DO |
|
***3 virulence factors of N. gonorrhea:***
|
1. adherence
2. antigenic variation 3. antibiotic R |
|
adherence of N. gonorrhea:
(2) |
1. pili for initial, long-range attachment
2. opacity prot's for tighter adhesion |
|
also on N. gonorrhea surface:
|
LOS
(~LPS) |
|
the following 3 factors of N. gonorrhea can undergo antigenic variation:
|
1. LOS
2. opacity prot's 3. pili |
|
N. gonorrhea antigenic variation is:
(2) |
1. spontaneous
2. frequent |
|
N. gonorrhea grows R to a drugs every:
|
20 years
|
|
only effective drug for N. gonorrhea on the market today =
|
ceftriaxone
|
|
Chlamydia spp are obligate:
|
**intracellular** bact
|
|
3 Chlamydia spp pathogenic to humans:
|
1. C. trachomatis
2. C. pneumoniae 3. C. psittaci |
|
C. psittaci infects:
|
parrots
- inhaling parrots feces dust will infect humans |
|
who gets infected more with Chlamydia?
|
women
|
|
trend of Chlamydia:
|
**rising steadily**
|
|
different strains of Chlamydia are differentiated by:
|
different surface proteins
=> ocular, genital, lymphogranuloma (genital warts) types |
|
C. trachomatis genital infections are often:
|
completely asymp
|
|
if C. trachomatis genital infections are symptomatic, they cause (3) in men:
|
1. non-gonococcal urethritis
2. epididymitis 3. proctitis |
|
if C. trachomatis genital infections are symptomatic in women, they cause:
(3) |
1. cervicitis
2. urethritis 3. PID |
|
symptoms of Chlamydia trachomatis infections are similar to:
|
gonorrheal infections
|
|
Chlamydial infections ~~
(2) |
1. mild local infections
2. severe PID - it's the inverse in gonorrhea |
|
complications of C. trachomatis genital infections for both men and women =
|
arthritis
|
|
compared to gonorrheal discharge, Chlamydial discharge is:
(2) |
more clear, watery
|
|
Chlamydial life cycle is unique:
(5 steps) |
1. EB's attach to epithelium
2. convert to RB's inside the cell 3. inclusion grows as RB's multiply 4. reconverted to EB's 5. released to infect other cells |
|
EB's =
(3) |
elementary bodies
1. extracellular form of Chlamydia 2. **infectious** 3. metabolically inactive |
|
RB's =
(3) |
reticulo-bodies
1. intracellular 2. non-infectious 3. metabolically active (divide/multiply) |
|
for energy, RB's use:
|
ATP from the host cell's mit
|
|
inclusion =
|
membrane that RB's divide and grow in
- recruits host mit to itself |
|
Chlamydia bacteriology:
(4) |
1. GN
2. has LPS and MOMP on the surface 3. small genome 4. energy parasite |
|
MOMP of Chlamydia =
|
major outer memb prot
|
|
pathogenesis of Chlamydia - infected epithelail cells release:
|
pro-inflammatory cytokines
=> PMN's, NK's, phag, APC's => continual chronic inflammation => necrosis, scarring |
|
diagnosis of BOTH gonorrhea and chlamydia: gold standard =
|
NAAT
- high sensitivity, specificity |
|
NAAT's are still positive within:
|
10-14 days after treatment
|
|
bacterial vaginosis can be caused by:
|
LOTS of different organisms
|
|
bacterial vaginosis is *common* - it occurs most with:
|
the sexually active, but also with those who are not active
|
|
bacterial vaginosis =
|
the alteration of normal vaginal flora, which is replaced with anaerobes
|
|
what is the normal vaginal flora?
|
Lactobacilli spp
|
|
*BV* flora ~~
|
absence of Lactobacilli and presence of large numbers of GN/GV coccobacilli
- called clue cells |
|
Lactobacilli produce the protective:
|
H2O2
|
|
2 pathogens associated with BV:
|
1. Garderella vaginalis
2. Mobiluncus spp - NOT ALWAYS present - could be secondary invaders instead of primary cause |
|
signs/symptoms of BV:
(3) |
1. discharge (normal or white)
2. elevated vaginal pH 3. strong odor |
|
diagnosis of BV: any 3 of the following:
(4) |
1. clue cells
2. pH >4.5 3. homogenous, adherent discharge 4. whiff test |
|
whiff test =
|
add drop of KOH, should be a fishy smell
|
|
adverse consequences of BV: associated with increased risk of:
(3) |
1. acquisition/transmission of HIV
2. other STI's 3. developing PID (if infected with GC/Chlamydia) |
|
in pregnant women, BV ~~
|
2x inc. risk for pregnancy problems
|
|
treatment of BV =
(3) |
1. metronidazole
2. clindamycin 3. try to prevent relapse (which is common) |
|
**treatment of BV does NOT:**
|
*reverse* adverse pregnancy risk
|
|
VVC stands for:
|
vulvovaginal candidiasis
|
|
VVC =
|
vaginal yeast infection
|
|
VVC occurs when:
|
protective Lactobacilli are eliminated *by antbibiotics*
=> **Candida spp overgrow** |
|
Candida species can be part of:
|
normal vaginal flora
|
|
prevalence of VVC is high in:
(3) |
1. pregnant
2. uncontrolled diabetes 3. immunocompromised |
|
80-90% of VVC is caused by:
|
Candida albicans
|
|
signs/symptoms of VVC =
(3) |
1. *itching*
2. chunky discharge - rare, but classic if present 3. penile erythema in partner |
|
filamentous form of C. albicans ~~
|
active form of disease
|
|
VVC does NOT depend on:
|
organism burden
- but rather to an allergic rxn despite low burden |
|
best diagnostic of VVC =
|
**wet mount**
|
|
treatment of VVC:
(2) |
1. short course of anti-fungals for uncomplicated cases
2. longer-term anti-fungals for complicated VVC's |
|
"complicated VVC's" ~~
|
underlying conditions, recurrence, immunocompromised
|
|
lower UTI is also called:
|
cystitis
|
|
cystitis =
|
bladder infection
|
|
symptoms of cystitis =
(5) |
1. inc. freq
2. dysuria 3. strongury 4. hematuria 5. changes in smell of urine |
|
strongury =
|
slow, painful urination
|
|
hematuria =
|
RBC's in urine
|
|
upper UTI is also called:
|
pyelonephritis
|
|
symptoms of pyelonephritis =
(4) |
1. fever
2. rigors 3. vomiting 4. loin pain |
|
onset of pyelonephritis is:
|
rapid
|
|
pyelonephritis can be prevented by:
|
treating cystitis
|
|
defenses against UTI's:
(5) |
1. defensins (local antimicrobials)
2. Lactobacilli 3. mucin layer to block adherence 4. lysozymes 5. Tamm-Horsfall Prot |
|
***what do Tamm-Horsful Prot's do?***
|
bind to UPEC that express *Type 1 pili*
=> inhibits UPEC's |
|
susceptibility to UTI's is:
|
50x greater in women than in men
- shorter urethra - pregnancy, spermacide, and normal intercourse also inc. risk for women |
|
recurrent UTI's ~~
|
blockage, *greater density of UPEC r's*
|
|
**a bladder infection in men is almost ALWAYS:**
|
indicative of a *different* condition
(not UTI) |
|
causes of UTI's:
(2) |
1. UPEC (80%)
2. Staph saprophyticus |
|
we're not sure if Staph saprophyticus causes:
|
**upper** UTI's
|
|
pathogenesis of UTI's: pathogen starts in:
|
intestines => urethra => bladder
=> form biofilm on inner surface of the bladder => pods that bulge out |
|
what causes the symptoms of UTI's?
|
TLR4-dependent host inflammatory response
|
|
**what is the key to UPEC virulence?**
|
adherence
|
|
UPEC's Type 1 pili are necessary for causing:
|
cystitis
- bring them from intestines all the way up through bladder |
|
what kind of pili are necessary for UPEC to cause pyelonephritis?
|
Pap pili
- necessary to attach to kidney epithelial cells |
|
UPEC adherence is directly proportional to:
|
severity of infeciton, chance of recurrence
|
|
biofilms form ________ a catheter
|
inside
|
|
diagnosis of UTI's: gold standard =
|
*quantitative* urine culture
- measures number of colony-forming bact. (or urine dipstick) |
|
treatment of UTI's:
(2) |
1. short course for e/o
2. proceed to long course if pt doesn't respond |
|
**caveat with treating UTI's:**
|
**watch out for yeast infections following UTI antibiotics**
|
|
asymp UTI is NOT:
|
treated
|
|
asymptomatic UTI's are not treated, EXCEPT in the case of:
(2) |
1. pregnant women
2. those about to undergo surgery |
|
cranberry juice may:
|
prevent UTI's,
but hard to say if if cures them |
|
defining property of all herpes viruses =
|
**latency**
|
|
**major differences between HSV and VZV = **
|
HSV ~~ local inf,
VZV ~~ dissemination to the LN's => skin |
|
VZV stands for:
|
varicella zoster virus
|
|
features of Herpes viruses:
(3) |
1. DNA
2. capsid 3. lipid membrane derived from host |
|
Herpes viruses are classified in 3 families; HSV1, HSV2, and VZV are all:
|
alphaherpes viruses
|
|
**3 features of alphherpes diseases:**
|
1. acute infection
2. latency in distinct locations 3. reactivated inf's |
|
acute herpes infections range from:
|
sub-clinical to mildly severe
|
|
both primary and reactivated inf's of Herpes virus are more severe in:
|
the immunocompromised
|
|
pathogenesis of herpes virus comes in 2 forms:
|
1. direct cell killing
2. immune-mediated disease |
|
immune-mediated disease as a result of herpes infection comes in the the form of:
(2) |
1. sepsis
2. corneal scarring |
|
corneal scarring is a result of:
|
repeated attacks against reactivating herpes virus in the eye
|
|
herpes infections are NOT:
|
seasonal
|
|
the vast majority of primary HSV1 and VZV infections occur in:
|
adolescents
|
|
how is HSV (both types) transmitted?
(3) |
1. saliva
2. lesions 3. sexual activity |
|
how is VZV transmitted?
|
respiratory droplets
|
|
what region does HSV1 tend to infect?
|
the orofacial area
|
|
what region does HSV2 tend to infect?
|
the genital area
|
|
lots of people get infected with HSV and:
|
NEVER experience symptoms
- 75% of people are seropositive for HSV1 |
|
**life cycle of herpes viruses:**
(3) |
1. DNA replicated in the nucleus
2. virions mature in the cytpoplasm 3. retrograde to neurons to become latent |
|
when a herpes virus becomes latent, its DNA:
|
turns from linear to circular, hiding itself as an episome in the neuron nucleus
|
|
what is the site of HSV1 latency?
|
the Trigeminal Ganglia
|
|
what is the site of HSV2 latency?
|
sacral ganglia (S2-S5)
|
|
what is the site of VZV latency?
(2) |
1. ALL DRG's
2. TG |
|
herpes: primary infection =>
|
retrograde to neurons => latency => reactivation
=> 1. retrograde to CNS (rare) => encephalitis 2. anterograde to eye/mouth/genital (HSV) or skin(VZV) |
|
symptoms of HSV1 infection:
(4) |
1. gingivostomatitis
2. pharyngitis 3. flu-like symptoms 4. herpetic whitlow on skin |
|
symptoms of HSV infections resolve in:
|
1-2 weeks
|
|
symptoms of HSV2 infection:
(1) |
genital sores
|
|
reactivated HSV infections =>
(4) |
1. cold sores
2. genital herpes 3. keratitis (=> corneal scarring) 4. *asymptomatic shedding* |
|
keratitis =
|
inflammation of the eye
|
|
asymptomatic shedding of HSV =
|
a significant source of transmission
|
|
primary infection of VZV =
|
chicken pox
=> itching, *non-uniform lesions* |
|
complications from primary VZV infections:
(2) |
1. rare in children
2. severe in adults |
|
quality of immunity to chicken pox after infection:
|
long-lasting
|
|
VZV spreads via:
|
coughing droplets,
since it disseminates to the lungs |
|
reactivated VZV infection =
|
Shingles
|
|
shingles =
|
rash in *dermatomes*
|
|
common complication of shingles =
|
post-herpetic neuralgia
|
|
neuralgia =
|
pain along a nerve
|
|
host responses to herpes infection:
(4) |
1. epigenetic/histone silencing of viral DNA
2. interferons => anti-viral state 3. PKR => inhibition of cell prot synth. 4. pro-inflammatory cytokines |
|
adaptive immune response to herpes infection:
(4) |
1. chemokines => T cells to site of inflammation
2. phag. by immature monocytes 3. killing by NK's via IL12 4. AB production |
|
one way that herpes combats the host is by:
|
spreading cell-to-cell to evade AB's
|
|
diagnosing HSV infectoin:
(2) |
1. look for CPE in affected tissue
2. ELISA |
|
**treatment of HSV/VZV:**
|
1. acyclovir (ACV)
2. related nucleoside analogs 3. forcarnet |
|
**how does ACV treat a herpes infection?**
|
P'n by viral thymidine kinase => enters nucleus => incorporated into viral DNA during elongation
=> missing 3' OH = can't form a phosphodiester bond => no elongation |
|
how does foscarnet work?
|
it's a pyrophosphate analog that
binds directly to the herpes virus DNA Polym, inactivating it |
|
Resistance to ACV is achieved by:
|
**absence of reduction of viral thymidine kinase**
=> DNA elongation proceeds |
|
R to ACV occurs almost exclusively in:
|
severely immunocompromised pts
|
|
if viral thymidine kinase is reduced (rather than absent), it can be overcome by:
|
a higher dose of ACV
|
|
HIV falls under the ____________ family
|
lentivirus
|
|
lentiviruses can infect:
|
non-dividing cells
|
|
HIV comes in 2 forms; of the two, HIV1 is far more:
|
pathogenic
- very diverse/variable too |
|
HIV features:
(4) |
1. ss RNA
2. enveloped 3. nucleocapsid too 4. 2 copies of genome |
|
***critical factors of HIV virulence:***
(2) |
1. RT, integrase, protease
2. gp120, gp41 |
|
what is gp120 necessary for?
|
***binding of CD4 receptor***
and secondary receptor too |
|
what is gp41 necessary for?
|
fusion of the HIV mlcl with the host cell
|
|
**HIV: 3 kinds of transmission:**
|
1. sexual
2. mother to child 3. parenteral |
|
3 kinds of mother-to-child HIV transmissions:
|
1. in utero
2. peripartum (around time of birth) 3. breast feeding |
|
3 parenteral transmission of HIV:
|
1. IVDU
2. needle stick 3. blood transfusion |
|
**life cycle of HIV:**
(5) |
1. entry via gp120, gp41
2. reverse transcription 3. integration of HIV DNA into human chromosome 4. protease cleavage to release 5. maturation once it's budded off |
|
***HIV binds specifically to:***
|
CD4 receptors
- and then to either CCR5 or CXCR4 receptor |
|
HIV replication/transcription ~~
|
TONS of mutations and recombinations
=> huge diversity |
|
(HIV tends to enter dividing cells =>
|
host machinery is co-opted immediately, to replicate the virus)
|
|
***acute HIV infections: virus enters => ***
|
encounters susceptible cells (either dc's or CD4+'s)
=> travels to the gut (no matter route of transmission) => depletes CD4+/CCR5+ cells in the gut => spreads to other tissues (LN's, blood, CNS) |
|
**the majority of CD4+/CCR5+ cells reside in:***
|
the gut
|
|
the initial AB response to HIV is:
|
weak and ineffective
|
|
host response to HIV =
(4) |
innate defensins, II, HIV-specific AB's, T cells
|
|
latency of HIV: during an acute infection, HIV can persist in some:
|
CD4+ cells
=> if these cells divide, you now have more copies of HIV, in the very cells that are supposed to eliminate |
|
why is there no cure for HIV?
(3) |
1. rapid rates of mutations
2. HIV infects the cells that are responsible for eliminating it 3. latency means we can't kill it off |
|
the rates of HIV disease progression vary widely; the average is:
|
10 years
- depends a lot on both viral AND host factors |
|
**only ONE chromosome encodes all of the host response factors to HIV:**
|
chrom. 6
|
|
initially, HIV uses ________; then, it mutates to use ________
|
CCR5;
CXCR4 |
|
what 2 factors determine the potential to develop AIDS?
|
1. HIV load
2. CD4+ count <200 |
|
HIV is diagnosed with:
|
ELISA
|
|
ELISA is VERY:
|
sensitive AND specific for HIV
|
|
**a positive ELISA test must be confirmed with:**
(3 options) |
1. Western blot
2. RNA PCR 3. DNA PCR |
|
target testing ~~
|
testing a specific hiigh-risk group
|
|
signs/symptoms of acute HIV infection =
(2) |
1. flu-like symptoms
2. PE flags |
|
7 PE flags for HIV:
|
1. oral thrush
2. Karposi's sarcoma on the heel 3. leukoplakia 4. shingles 5. chelitis 6. seborrheic dermatitis 7. severe HSV inf |
|
infections associated with HIV (if CD4+ >200):
(3) |
1. STI's
2. TB 3. strep pneumoniae |
|
TB is HIV patients: the lower the CD4+ count,
|
the LESS typical TB looks
- doesn't form granulomas - PPD's are often false neg's - but response to TB therapy is the same |
|
with AIDS, secondary infections tend to be:
|
bugs of LOWER pathogenic potential
|
|
***most common opportunistic infection in AIDS patients = ***
|
PCP
|
|
PCP stands for:
|
pneumocystis jiroveci pneumonia
(fungus) |
|
nearly ALL AIDS pts have:
|
PCP
|
|
hallmark of PCP =
|
SOB/desat
|
|
cryptococcus infection following AIDS =>
|
meningitis
|
|
3 other opportunistic infections following AIDS:
|
1. CMV reactivation
2. Myco TB 3. Myco avium |
|
lots of cancers occur as a results of HIV infection; common one =
|
Kaporsi's sarcoma
|
|
KS is caused by:
|
HHV-8
|
|
AIDS-related cancers of the CNS:
93) |
1. toxoplasmosis
2. primary CNS lymphoma 3. PML |
|
PML (a leukemia) is caused by:
|
the JC virus
|
|
goal of HIV therapy =
|
suppress replication
|
|
if HIV isn't replicating, it can't:
|
mutate
|
|
HIV mutates at a rate of:
|
2000 x's a day
|
|
***HAART =
|
combo antiviral therapy
|
|
combos of drugs for HIV are necessary for:
|
survival
(except for the very few) |
|
these days, HAART comes in the form of:
|
3 meds in one pill, once daily
|
|
HIV therapy DOES:
|
increase CD4+ cells
- initially a rapid increase, then a gradual one |
|
5 targets of inhibition when treating HIV:
|
1. attachment (via gp120, gp40)
2. fusion 3. RT 4. integrase 5. protease |
|
RT, integrase, and protease are all:
|
excellent targets, b/c humans don't have them
|
|
inflammatory reconstitution syndrome =
|
systemic, prolonged fever due to reawakened host response to pathogens
|
|
latency of HIV =
|
we can't cure it
- stop therapy => HIV comes out of hiding and replicates again |
|
R IS an issue in:
|
HIV meds
|
|
HPV features:
(3) |
1. DNA in circular episome
2. common in mammals 3. cause warts |
|
the HPV replication cycle is closely associated with:
|
the differentiation state of the epithelial cell
|
|
HPV infection: microwound =>
|
access to basal epithelial cells
=> infection of basal cells => expression of viral DNA as cells differentiate => replication => release at the top (stratum corneum) |
|
which HPV prot's are responsible for viral DNA replication?
|
E1/E2 heterodimer
|
|
what does HPV's E2/E2 homodimer do?
|
suppresses HPV's E6 and E7 expression
|
|
2 different warts that HPV causes:
|
1. condylomas
2. skin warts (on hands and feet) |
|
condylomas are _______ warts; they appear in:
(2) |
**mucosal** warts
==> genitals, oropharynx |
|
HPV warts tend to resolve:
|
quickly
|
|
in order for HPV to infect, there MUST be a:
|
break in the skin
|
|
it's VERy common to have had:
|
HPV
|
|
in RARE cases, HPV can cause:
(2) |
1. cervical cancer
2. oral squamous cell carcinoma |
|
cervical cancer ~~
(2) |
1. discharge and abnormal vaginal bleeding
2. dysplasia (enlargement) or neoplasia |
|
cervical cancer is usually a:
|
squamous-cell carcinoma
- sometimes adenocarcinoma (of glands) |
|
***first step to cancer from HPV infection =
|
***integration of HPV episome into host genome***
|
|
**what happens with integration of HPV episome into host genome?**
|
**E2/E2 gets disrupted => E6, E7 NOT suppressed
|
|
***what happens when E6 and E7 are NOT suppressed?***
(2) |
1. host cells continue to divide
2. apoptosis does NOT occur |
|
only the "high-risk" serotypes fail to suppress E6, E7; that's why:
|
cancer from HPV infection is rare
|
|
diagnosis of HPV =
(2) |
1. genital warts
2. cervical changes from pap smear |
|
vaccines for HPV =
(2) |
1. Gardasil
2. Cervarix |
|
treatment of HPV infection =
|
removal of warts
|
|
WBC’s in the stool ~~
|
**inflammatory diarrhea**
|
|
only Shigella dysentariae releases:
|
Shiga toxin
|
|
syphilis damages cells ==>
|
cardiolipin
|
|
lytic infection = normal inf =
|
virus replicates a lot, eventually lysing the cell in release
|
|
clinical symptoms of lytic infections are the result of:
(2) |
1. tissue damage due to viral replication
2. immune response to infection |
|
lytic infections tend to last:
|
2-14 days
|
|
**chronic infections ** =
|
continual infection = long lytic infections
- viruses are released from cells, but cells DON'T lyse |
|
**chronic infections are a subset of lytic infections; main difference between the two = **
|
time to clear
- lytic ~ <2 weeks - chronic ~ wks/mths/years |
|
2 types of chronic infection:
|
1. focal
2. diffuse |
|
focal chronic infection =
(3) |
1. carrier cells produce virus
2. infect neighboring cells 3. die, but neighboring cells continue the cycle |
|
diffuse chronic infection =
(2) |
1. viruses replicate in infected cells that also replicate
2. cells shed viruses for their lifetime |
|
Hep C ~~
|
persistent (chronic) viral infection
- eventually leads to cirrhosis |
|
***latency =
|
presence of viral nucleic acids in the absence of infectious virus
|
|
**difference between chronic and latent infections:**
|
chronic infections produce infectious viruses;
latent infections DON'T |
|
3 phases of latency:
|
1. getting in
2. maintenance (staying in) 3. reactivation (getting out) |
|
establishment of latency (getting in) ~~
|
virus stops expressing proteins
|
|
**while BOTH RNA and DNA viruses can become latent, the viral genome in *either case* is maintained as:**
|
DNA
|
|
provirus =
|
latent DNA *integrated* into host genome
e.g. HIV |
|
episomal latency =
|
latent viral DNA is maintained extra-chromosomally
- e.g. herpes |
|
latently-infected cells tend to:
(2) |
1. proliferate less
2. have less metabolic demand |
|
latency last for:
|
months to years
- long |
|
reactivation of latent virus occurs in response to:
|
1. stimuli for host cell to diff/prolif
2. cell stress that would cause cell death - get out of there |
|
diagnosis of latent viral infection has to be via:
|
PCR of the viral genome
- searching for antigen or infectious virus is either misleading or pointless |
|
latent infections CAN cause diseases, in the form of:
(2) |
1. cancer
2. lympho-proliferative disorders (too many WBC's) |
|
latent EBV =>
|
cancer
|
|
latent herpes =>
|
KS
|
|
latent viruses are transmissible via:
|
transplants
- latently-infected cells get transferred to recipient |
|
best example of a latent virus that reactivates after a transplant:
|
HCMV
- delayed onset is worse than onset within a year |
|
a cure for latent viruses should focus on those patients in whom:
|
the latency keeps springing up into active infection
- leave the others alone |
|
one method of treating HIV latency =
|
forcing it to reactive,
=> hit it with antivirals to prevent integration/replication => progressive rounds of treatment to eliminate latent reservoir |
|
leading disease due to nosocomial infection =
|
pneumonia
|
|
placement of catheter outside of the OR =>
|
increased risk of nosocomial infection
|
|
HAP =
|
hospital-acquired pneumonia
|
|
VAP =
|
ventilator-associated pneumonia
|
|
HCAP =
|
health care-associated pneumonia
- contracted in the outpatient/home-care setting |
|
ranking of most risk for MDR and m/m:
|
HAP/VAP > HCAP > CAP
|
|
aspiration = huge risk for:
|
nosocomial penumonia
|
|
VAP prevention bundle:
(4) |
1. 30-45 degress
2. consider extubating ASAP 3. prevent peptic ulcer disease/ reflux 4. prevent DVT |
|
bloodstream infections: major risk =
|
use of intravascular devices
e.g. central line |
|
3 major organisms that exhibit R in hospitals:
|
1. Staph aureus
2. VRE 3. C. diff |
|
Staph aureus ~~
(3) |
BSI's, pneumonia, surgical infections
|
|
Staph aureus is implicated in:
|
nearly every nosocomial infection
|
|
risk factors for developing Staph aureus R:
(3) |
1. ab use
2. prolonged stay 3. proximity to patients with MRSA |
|
Staph aureus are actually:
|
normal flora of the nasopharynx
|
|
both Staph aureus and VRE are transmitted via:
|
hands/surfaces
|
|
VRE =
|
vancomycin-R enterococci
|
|
VRE aren't:
|
normal flora
|
|
C. diff =
|
normal flora of GI tract
|
|
to which bact. does Toxin A and Toxin B belong to?
|
Clostridium difficile
|